Lilly rides Mounjaro, Zepbound to better
Time:2024-05-22 01:56:46 Source:businessViews(143)
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Previous:Kristin Cavallari, 37, ignores critics of her age
Next:China's first intelligent offshore drilling platform installed
You may also like
- Padres second baseman Xander Bogaerts leaves game against Braves with shoulder injury
- Arizona is boosting efforts to protect people from the extreme heat after hundreds died last summer
- Israel has briefed US on plan to evacuate Palestinian civilians ahead of potential Rafah operation
- Kate Hudson makes TV debut performing as singer on The Tonight Show Starring Jimmy Fallon
- Wildfires sweep across Finland, straining rescue services
- Khloe Kardashian shows off her curves in form
- Kansas has a new border security mission and tougher penalties for killing police dogs
- Toney's goal drought continues after Brentford draws 0
- Pentagon vows to keep weapons moving to Ukraine as Kyiv faces a renewed assault by Russia